

( )

:

HDL

( / / )

NCEP(ATP III)

/ / ( ECG -IHD)

/ /

/ P= / )

(OR= / P= / )

(OR= / P< / )

(OR = / CI: /

(OR= / P= / ) HDL

:

\*

: .

\*\* \*

/

/

. ( )

HDL

. ( )

NHANES III<sup>3</sup>

. ( )

" "

. ( )

ATP

. ( )

" III"<sup>1</sup>

. ( )

NCEP<sup>2</sup>

. ( )

)

(

HDL

)

(

(

(

/

. ( )

ATP III-NCEP

. ( )

. ( )

:

: I

: II

<sup>3</sup> NHANES III: National Health And Nutrition Examination Survey III

<sup>1</sup> ATP III: Adult Treatment Panel III

<sup>2</sup> NCEP: National Cholesterol Education Program

« Standimeter »

BMI.(

ECG .

Selectra 2 autoanalyzer (Vital " specific,The Netherlands )

colorimetric method )

(enzymatic glucose oxidase

( Pars Azmun Inc;Tehran, Iran)

HDL

( oxidase phenol aminoantipyrine cholesterol)

)

enzymatic – method glycerol -3 phosphate

( oxidase phenol aminoantipyrine

Friedman ) LDL

( Formula

: (

National cholesterol Education)

Program's Adult Treatment panel III "

"(ATP III

: « WHO MONICA »

/ /

---

: HDL

/ )

( /

:

:

( / )

( / )

/ ) / (IHD-ECG) .( )

( P < / /

.( ) ATP(III)

ECG

.

( / )

( / )

IHD ECG

:

(

\*

Chi-square

" Two-Tailed test"

P > /

IHD-ECG

( OR= / CI= / / P= / )}

/ - / P= / )

.{ ( OR= / CI= )

(

IBM

SPSS 9.05 (SPSS Inc;Chicago,IL)

( OR= / ) (OR= / )

(OR= / ) HDL

( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )
( / )	( / )	( / )	( / )	( / )	( / )

(

/	/	/	
/	/	/	
/	/	/	
/	/	/	
/	/	/	( )
/	/	/	( )

P.value	C.I	OR	
/	( / / )	/	
/	( / /	/	( )
/	( / / )	/	
/	( / / )	/	
/	( / / )	/	

/

.( )

/

ATP III

/

—

—

" " "

" " "

" NCEP" " WHO" .( )

.( ) /

/ /

NCEP

—

WHO

—

.( )

" "

WHO .(P< / )

.( )

Bruneck study

.( )

/

.( ) /

.( )

.( )

Atherosclerosis Risk in ( OR= / P< / )

Communities Study

" ATP III"

\_\_\_\_\_

.( )

COX  
/

( OR= / ) . / .( )  
.( )(OR = / )

.(OR = / ) .( )

" "  
.( )

OR= / ) .  
.( OR= /

HDL

.( )

ATP III

HDL

Kaunas

.( )

---

## References:

---

1. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. *Circulation* 2003;108:420-425.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-2497.
3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metab Clin N Am* 2004;33:351-375.
4. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. *Diabetes Care* 2003;26:1251-1257.
5. Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diab Res Clin Pract* 2003;61:29-37.
6. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. *Circulation* 2004;110:1245-1250.
7. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. *Prev Cardiol* 2005;8:47-54.
8. Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. *Circulation* 2004;109:42-46.
9. Vitarius JA. The metabolic syndrome and cardiovascular disease. *Mount Sinai J Med* 2005;72:257-262.
10. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care* 2004;27:2444-2449.
11. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP metabolic syndrome. The French D. E.S.I.R. study. *Diabet Metab* 2003;29:526-32.
12. Hunt KJ, Resendez RG, Williams K, et al. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;110:1251-1257.
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-2716.
14. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. *Diabetes Care* 2005;28:385-390.
15. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. *Arch Intern Med* 2005;165:1192-8.
16. Cerniauskiene LR, Reklaitiene R, Luksiene DI, et al. Association of metabolic syndrome with ischemic heart disease among middle-aged Kaunas population. *Medicina* 2005;41:435-41.
17. Lindblad U, Langer RD, Wingard DL, et al. Metabolic syndrome and ischemic heart disease in elderly men and women. *Am J Epidemiol* 2001;153:481-9.